Diego Bonilla Arcos1, Jerry A Krishnan2, R William Vandivier3, Jonathan E Sevransky4, William Checkley5, Tyree H Kiser6, Jamie L Sullivan7, John W Walsh5, Robert A Wise5, Kevin C Wilson. 1. The Pulmonary Center, Boston University School of Medicine, Massachusetts. 2. University of Illinois Hospital and Health Sciences System, Chicago. 3. Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Denver Anschutz Medical Campus, Denver. 4. Division of Pulmonary and Critical Care Medicine, Emory University, Atlanta, Georgia. 5. Division of Pulmonary and Critical Care, School of Medicine, Johns Hopkins University, Baltimore, Maryland. 6. Department of Clinical Pharmacy, University of Colorado Denver Anschutz Medical Campus, Denver. 7. COPD Foundation, Washington, D.C.
Abstract
Background: Treatment of an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) with systemic steroids reduces treatment failure, shortens hospital length of stay, improves lung function, and reduces dyspnea. However, it can also cause hyperglycemia, delirium, fluid retention, and other side effects. The balance of these desirable and undesirable effects probably varies according to the steroid dose. Methods: We asked the question, "Should patients having an AECOPD receive low-dose or high-dose systemic steroids?" We searched Medline and the Cochran Central Register of Controlled Trials (CENTRAL) using a sensitive search strategy built around the medical subject heading, "COPD," and variations of the keywords exacerbation, steroids, and randomized trials. Our search yielded 1702 articles in Medline and 885 articles in CENTRAL; we reviewed the full text of 35 articles and selected 11 studies that met the following conditions: randomized trial, enrolled patients having an AECOPD, compared one systemic steroid regimen to another, measured clinical outcomes, and was published in a peer-reviewed journal. Results: None of the selected trials directly compared the effects of different systemic steroid doses on clinical outcomes in patients with AECOPD. Four trials compared durations of steroid treatment, 3 trials compared types of steroids, 1 trial compared routes of steroid delivery, and 3 trials compared multiple variables. Conclusion: There is a paucity of data to support the selection of a systemic steroid dose in patients having an AECOPD. Randomized trials that measure patient-centered outcomes and compare doses of systemic steroids in patients having an AECOPD are needed.
Background: Treatment of an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) with systemic steroids reduces treatment failure, shortens hospital length of stay, improves lung function, and reduces dyspnea. However, it can also cause hyperglycemia, delirium, fluid retention, and other side effects. The balance of these desirable and undesirable effects probably varies according to the steroid dose. Methods: We asked the question, "Should patients having an AECOPD receive low-dose or high-dose systemic steroids?" We searched Medline and the Cochran Central Register of Controlled Trials (CENTRAL) using a sensitive search strategy built around the medical subject heading, "COPD," and variations of the keywords exacerbation, steroids, and randomized trials. Our search yielded 1702 articles in Medline and 885 articles in CENTRAL; we reviewed the full text of 35 articles and selected 11 studies that met the following conditions: randomized trial, enrolled patients having an AECOPD, compared one systemic steroid regimen to another, measured clinical outcomes, and was published in a peer-reviewed journal. Results: None of the selected trials directly compared the effects of different systemic steroid doses on clinical outcomes in patients with AECOPD. Four trials compared durations of steroid treatment, 3 trials compared types of steroids, 1 trial compared routes of steroid delivery, and 3 trials compared multiple variables. Conclusion: There is a paucity of data to support the selection of a systemic steroid dose in patients having an AECOPD. Randomized trials that measure patient-centered outcomes and compare doses of systemic steroids in patients having an AECOPD are needed.
Authors: Bartolome R Celli; Marc Decramer; Jadwiga A Wedzicha; Kevin C Wilson; Alvar Agustí; Gerard J Criner; William MacNee; Barry J Make; Stephen I Rennard; Robert A Stockley; Claus Vogelmeier; Antonio Anzueto; David H Au; Peter J Barnes; Pierre-Regis Burgel; Peter M Calverley; Ciro Casanova; Enrico M Clini; Christopher B Cooper; Harvey O Coxson; Daniel J Dusser; Leonardo M Fabbri; Bonnie Fahy; Gary T Ferguson; Andrew Fisher; Monica J Fletcher; Maurice Hayot; John R Hurst; Paul W Jones; Donald A Mahler; François Maltais; David M Mannino; Fernando J Martinez; Marc Miravitlles; Paula M Meek; Alberto Papi; Klaus F Rabe; Nicolas Roche; Frank C Sciurba; Sanjay Sethi; Nikos Siafakas; Don D Sin; Joan B Soriano; James K Stoller; Donald P Tashkin; Thierry Troosters; Geert M Verleden; Johny Verschakelen; Jorgen Vestbo; John W Walsh; George R Washko; Robert A Wise; Emiel F M Wouters; Richard L ZuWallack Journal: Am J Respir Crit Care Med Date: 2015-04-01 Impact factor: 21.405
Authors: Sean P Shortall; James Blum; Frederick A Oldenburg; Lorraine Rodgerson; John M Branscombe; Edward M Harrow Journal: Respir Care Date: 2002-02 Impact factor: 2.258
Authors: Jörg D Leuppi; Philipp Schuetz; Roland Bingisser; Michael Bodmer; Matthias Briel; Tilman Drescher; Ursula Duerring; Christoph Henzen; Yolanda Leibbrandt; Sabrina Maier; David Miedinger; Beat Müller; Andreas Scherr; Christian Schindler; Rolf Stoeckli; Sebastien Viatte; Christophe von Garnier; Michael Tamm; Jonas Rutishauser Journal: JAMA Date: 2013-06-05 Impact factor: 56.272
Authors: Ynze P de Jong; Steven M Uil; Hans P Grotjohan; Dirkje S Postma; Huib A M Kerstjens; Jan W K van den Berg Journal: Chest Date: 2007-07-23 Impact factor: 9.410
Authors: Tyree H Kiser; Jonathan E Sevransky; Jerry A Krishnan; James Tonascia; Robert A Wise; William Checkley; John Walsh; Jamie B Sullivan; Kevin C Wilson; Alan Barker; Marc Moss; R William Vandivier Journal: Chronic Obstr Pulm Dis Date: 2017-07-15